Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia

Leukemia volume 22, pages 1291–1293 (2008)Cite this article

B-cell chronic lymphocytic leukemia (B-CLL) is a heterogeneous malignant disease that involves deregulated apoptosis. Overexpression of anti-apoptotic proteins of the BCL-2 (B-cell lymphoma gene-2) family such as BCL-2 and MCL-1 (myeloid cell leukemia-1) is commonly detected in B-CLL. Higher levels of MCL-1 have been correlated with a poor treatment response.1 MCL-1 gene silencing by RNA interference was reported to induce apoptosis in B-CLL cells, suggesting that the MCL-1 gene might be a therapeutic target.2 Still, the impact of different MCL-1 gene expression levels on the prognosis of B-CLL patients remains unknown.

To address this issue, we quantified the expression of MCL-1 gene in 119 B-CLL patients and correlated the results with patient survival and known prognostic markers.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–3389.

    CAS  PubMed  Google Scholar 

  2. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007; 13: 2144–2150.

    Article  CAS  PubMed  Google Scholar 

  3. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA et al. Interleukin-6 upregulates myeloid cell leukaemia-1 expression through a STAT3 pathway in cholangiocarcinome cells. Hepatology 2005; 42: 1329–1338.

    Article  CAS  PubMed  Google Scholar 

  4. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 2003; 17: 2474–2486.

    Article  CAS  PubMed  Google Scholar 

  5. Montserrat E . New prognostic markers in CLL. Hematol Am Soc Hematol Educ Program 2006, 279–284.

    Article  Google Scholar 

  6. Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005; 23: 3780–3792.

    Article  CAS  PubMed  Google Scholar 

  7. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M . Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 1996; 69: 114–119.

    Article  CAS  PubMed  Google Scholar 

  8. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112–121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Université Clermont 1, UFR Médecine, CHU Clermont-Ferrand, Service de Cytogénétique Médicale, Clermont-Ferrand, France

    L Véronèse, C Goumy, P Vago & A Tchirkov

  2. EA 3846, Université d'Auvergne, Clermont-Ferrand, France

    L Véronèse, P Verrelle, E Chautard & A Tchirkov

  3. Service d'Hématologie Clinique, CHU Clermont-Ferrand, Clermont-Ferrand, France

    O Tournilhac & P Travade

  4. Departement de Radiothérapie, Centre Jean Perrin, Clermont-Ferrand, France

    P Verrelle & A Tchirkov

  5. Service d'Hématologie Biologique & Université Pierre et Marie Curie, Hôpital Pitié-Salpêtrière, Paris, France

    F Davi

  6. Institut Pasteur de Montevideo, Montevideo, Uruguay

    G Dighiero

  7. Service d'Hématologie Biologique, CHU Clermont-Ferrand, Clermont-Ferrand, France

    R Veyrat-Masson

  8. Service Statistiques et Communications Médicales, Centre Jean Perrin, Clermont-Ferrand, France

    F Kwiatkowski

Authors
  1. L Véronèse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O Tournilhac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Verrelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Davi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Dighiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Chautard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Veyrat-Masson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Kwiatkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Goumy
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Vago
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Travade
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Tchirkov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Tchirkov.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Véronèse, L., Tournilhac, O., Verrelle, P. et al. Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia. Leukemia 22, 1291–1293 (2008). https://doi.org/10.1038/sj.leu.2405052

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2405052

This article is cited by

Search

Advanced search

Quick links